Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Type 1 Diabetes

Type 1 Diabetes

Part of Diabetes

Subtypes of Type 1 Diabetes

Type 1 diabetes mellitus 10 Wolfram Syndrome 1

52 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Type 1 Diabetes

203 trials tracked for Type 1 Diabetes: 39 in phase 3 or 4 and 14 with published results. The most-cited published study has 179 citations.

203Trials tracked
39Phase 3 & 4
0Recruiting
14With published results
Phase distribution
Phase 4 14 Phase 3 25 Phase 2 29 Phase 1 9 Other / NA 126
  1. Phase 3 Metformin Therapy for Overweight Adolescents With Type 1 Diabetes Completed · 179 cited
  2. Phase 3 EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes Completed · 143 cited
  3. Phase 3 Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients Completed · 62 cited
  4. Phase 3 A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy Completed · 44 cited
  5. Phase 4 52 Week Trial of Liraglutide in Type 1 Diabetes Completed · 38 cited
  6. Phase 4 Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus Completed · 14 cited
Show 44 more trials
  1. Phase 3 Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy Completed · 7 cited
  2. Phase 4 Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes Completed · 6 cited
  3. Phase 4 Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Completed · 6 cited
  4. Phase 4 Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings Completed · 5 cited
  5. Phase 3 Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1) Completed · 4 cited
  6. Phase 3 A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus Completed · 2 cited
  7. Phase 4 A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus Completed · 1 cited
  8. Phase 4 A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes Completed · 1 cited
  9. Phase 4 Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia Completed
  10. Phase 4 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes Completed
  11. Phase 4 New Onset Type 1 Diabetes: Role of Exenatide Completed
  12. Phase 4 Insulin Pump to Multiple Daily Injection Transition Clinical Trial Completed
  13. Phase 4 Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes Completed
  14. Phase 4 Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose Completed
  15. Phase 4 Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness Completed
  16. Phase 3 Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon Completed
  17. Phase 3 A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes Completed
  18. Phase 3 Liraglutide In Overweight Patients With Type 1 Diabetes Completed
  19. Phase 3 Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes Completed
  20. Phase 3 Liraglutide in Type 1 Diabetes Completed
  21. Phase 3 Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes Completed
  22. Phase 3 Liraglutide in Adolescents With Type 1 Diabetes Completed
  23. Phase 3 A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D Completed
  24. Phase 3 Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration Completed
  25. Phase 3 Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon Completed
  26. Phase 3 Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature Completed
  27. Phase 3 STEP: Social Support To Empower Parents Completed
  28. Phase 3 Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes Completed
  29. Phase 3 Diabetic Retinopathy Candesartan Trials Completed
  30. Phase 3 New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy Completed
  31. Phase 3 DIabetic Retinopathy Candesartan Trials. Completed
  32. Phase 3 Liraglutide in the Treatment of Type 1 Diabetes Mellitus Completed
  33. Phase 3 Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes Completed
  34. Phase 2 Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes Completed
  35. Phase 2 CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Completed
  36. Phase 2 Transdermal Basal Insulin Patch Study in Type 1 Diabetes Completed
  37. Phase 2 Incretin Effect and Use After Clinical Islet Transplantation Completed
  38. Phase 2 Naltrexone and Hypoglycemia in Type 1 Diabetes Completed
  39. Phase 2 Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting Completed
  40. Phase 2 Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20) Completed
  41. Phase 2 DiaBetter Together for Young Adults With Type 1 Diabetes Completed
  42. Phase 2 Diabetes Prevention - Immune Tolerance Completed
  43. Phase 2 Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes Completed
  44. Phase 2 A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED) Completed

Showing the 50 most-cited and recently-updated of 203 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Type 1 Diabetes: what the trials found

Clinical trials for Type 1 Diabetes have evaluated various pharmacological and delivery interventions. Insulin Glargine was assessed regarding Time-in-Range (TIR), time in hypoglycemia, and time in serious hypoglycemia; however, no statistically significant differences were observed between groups across these metrics 14.

Multiple daily injections using a combination of Insulin Degludec and Insulin Aspart showed varying results compared to the control group: the treatment group had higher time spent with glucose levels >180 mg/dL (46.3% vs 38.5%), lower time in hypoglycemia <70 mg/dl (3.9% vs 2.1%), and lower Time-in-Range (47.8% vs 56.5%) 19.

Rapid-acting insulin was evaluated for its impact on caregiver treatment adherence and glycemic variability, with results showing significant differences in these metrics at the 1-month and 4-month post-intervention marks 16.

Insulin Degludec did not show statistically significant changes in mean percent Time in Range, Coefficient of Variation of TIR, or Nocturnal Time in Range (70-180 mg/dL) 17.

Recent results — preliminary, needs further review

  • The AIDANET system showed significantly higher TIR during 18-hour hotel sessions compared to at-home settings (85.7% vs 71.7%, p=0.02) 1.
  • Tandem t:slim X2 with extended bolus demonstrated a TIR of approximately 71-73% and 0% time in hypoglycemia 2.
  • MPC closed-loop systems showed significantly lower incremental Area Under the Curve of postprandial glucose following the first meal (18.1 vs 20.9, p=0.017) 6.
  • Psychoeducation to reduce diabetes distress did not result in statistically significant improvements in TIR, A1c, or distress scores 3.

For the clinician treating this condition

  • Insulin Glargine and Insulin Degludec showed no statistically significant differences in primary glycemic metrics such as Time-in-Range or hypoglycemia duration compared to controls [14, 17].
  • Combination therapy of Insulin Degludec and Insulin Aspart resulted in higher instances of hyperglycemia (>180 mg/dL) but lower rates of hypoglycemia (<70 mg/dl) compared to the control group 19.
  • Advanced delivery systems like AIDANET showed significantly improved Time-in-Range during specific high-variability scenarios (e.g., hotel sessions) compared to at-home settings 1.

AI synthesis of 8 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Genetic study links H. pylori susceptibility to HLA and innate immunity genes, suggests causal disease relationships
Gastroenterology Meta-analysis
Genetic study links H. pylori susceptibility to HLA and innate immunity genes, suggests causal disease relationships Large genetic study finds links between H. pylori infection susceptibility and autoimmune diseases
A meta-analysis of up to 140,863 Japanese and European individuals identified significant genetic associations for H.
A large genetic study reveals specific immune system genes linked to H. pylori infection and autoimmune diseases like type 1 diabetes and Ha…
medRxiv Apr 2, 2026
Chinese APS-1 patients show recurrent AIRE gene deletion, male predominance, and low classic triad incidence
Dermatology Cohort
Chinese APS-1 patients show recurrent AIRE gene deletion, male predominance, and low classic triad incidence What makes autoimmune syndrome APS-1 different in Chinese patients?
A case report and systematic narrative review of 25 genetically confirmed Chinese APS-1 patients identified a recurrent deletion of AIRE gen…
A new look at 25 genetically confirmed Chinese patients with APS-1 found a specific AIRE gene deletion and a surprising trend where twice as…
Frontiers Apr 2, 2026
GADA test shows high specificity but moderate sensitivity for adult-onset type 1 diabetes
Diabetes & Endocrinology Meta-analysis
GADA test shows high specificity but moderate sensitivity for adult-onset type 1 diabetes How well does a common blood test spot adult-onset type 1 diabetes?
A systematic review and meta-analysis of 11,760 adults with newly diagnosed diabetes found GADA testing had pooled sensitivity of 0.53 and s…
A common blood test misses half of adult-onset type 1 diabetes cases, meaning a negative result doesn't fully rule out the disease.
Frontiers Apr 2, 2026
Meta-analysis finds 8.33% pooled prevalence of new-onset diabetes after SARS-CoV-2 infection in adults
Diabetes & Endocrinology Meta-analysis
Meta-analysis finds 8.33% pooled prevalence of new-onset diabetes after SARS-CoV-2 infection in adults Study finds link between COVID-19 infection and new diabetes diagnoses in adults
A systematic review and meta-analysis of 33 observational studies in adults following SARS-CoV-2 infection found a pooled prevalence of new-…
About 8.3% of adults develop new diabetes after COVID-19 infection, with type 2 cases making up most of the diagnoses in a review of 33 stud…
Apr 2, 2026

Research across Diabetes

Related studies from across the Diabetes family.

Proposed pathway for systematic MASLD/MASH assessment in type 2 diabetes
Diabetes & Endocrinology Sys. Review
Proposed pathway for systematic MASLD/MASH assessment in type 2 diabetes New Pathway Proposed to Manage Liver Disease in Diabetes Patients
This narrative review proposes a structured, risk-adapted outpatient pathway for MASLD/MASH assessment in patients with type 2 diabetes, sta…
A new proposed management plan aims to help people with type 2 diabetes identify and assess liver conditions more systematically.
Frontiers Jul 30, 2026
OSAS not significantly tied to diabetic retinopathy overall, but risk doubles in Asian subgroups
Diabetes & Endocrinology Meta-analysis
OSAS not significantly tied to diabetic retinopathy overall, but risk doubles in Asian subgroups Sleep Apnea Link to Diabetic Retinopathy Varies by Region
This meta-analysis of 599,405 patients with type 2 diabetes found no significant overall association between obstructive sleep apnea syndrom…
New data suggests that the link between sleep apnea and eye damage in people with type 2 diabetes depends on location and testing methods.
Frontiers Jul 30, 2026
Oral-health promotion improves outcomes for adults with type 2 diabetes when guidance is provided
Diabetes & Endocrinology Sys. Review
Oral-health promotion improves outcomes for adults with type 2 diabetes when guidance is provided Oral health care is often missed in type 2 diabetes management
This scoping review of 9 peer-reviewed studies examines oral-health promotion and prevention in adults with type 2 diabetes. The authors fin…
Many people with type 2 diabetes do not know their oral health is at risk, and doctors often provide inconsistent guidance on how to manage …
Frontiers Jul 30, 2026
SGLT2 inhibitors and GLP-1 receptor agonists show similar MACE reduction in type 2 diabetes
Diabetes & Endocrinology Meta-analysis
SGLT2 inhibitors and GLP-1 receptor agonists show similar MACE reduction in type 2 diabetes Trial shows similar heart benefits for two diabetes medications
This systematic review and network meta-analysis compared SGLT2 inhibitors and GLP-1 receptor agonists for major adverse cardiovascular even…
Two common types of diabetes drugs both show significant reductions in major heart events for patients with a history of heart attacks.
Frontiers Jul 29, 2026
Bibliometric analysis reveals expanding multidisciplinary research landscape for diabetes-related hearing loss
Rheumatology Sys. Review
Bibliometric analysis reveals expanding multidisciplinary research landscape for diabetes-related hearing loss Diabetes and hearing loss: a growing link researchers are mapping
This systematic bibliometric review analyzed 1,622 publications to map the global research landscape of diabetes and hearing loss. The study…
A new analysis of 1,622 publications reveals a strong, growing link between diabetes and hearing loss, with research shifting toward age-rel…
Frontiers Jul 28, 2026
Incretin-based weight loss lower in type 2 diabetes trials, but confounded by demographics
Nutrition & Obesity Medicine Meta-analysis
Incretin-based weight loss lower in type 2 diabetes trials, but confounded by demographics Weight loss with incretin drugs may depend on patient profile
This meta-regression found that placebo-adjusted weight loss with incretin-based therapies was significantly lower in type 2 diabetes trials…
People with type 2 diabetes may lose less weight on incretin drugs, but it's likely due to other health factors, not diabetes itself.
Jul 28, 2026
Vitamin D deficiency is prevalent among African patients with Type 2 Diabetes and higher HbA1c
Diabetes & Endocrinology Meta-analysis
Vitamin D deficiency is prevalent among African patients with Type 2 Diabetes and higher HbA1c Vitamin D Deficiency Linked to Higher Blood Sugar in Diabetes
This meta-analysis of observational studies across 11 African countries found a 51% prevalence of Vitamin D deficiency in individuals with T…
A large study of patients across 11 African countries found that vitamin D deficiency is linked to higher blood sugar levels in people with …
Jul 25, 2026
GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios
Diabetes & Endocrinology Sys. Review
GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios Incretin Drugs Show Heart Benefits Across Multiple Conditions
This state-of-the-art review synthesizes evidence regarding incretin analogues, specifically GLP-1 receptor agonists and tirzepatide. The re…
GLP-1 drugs and tirzepatide prove heart benefits in diabetes, obesity, heart failure, and more.
Frontiers Jul 25, 2026
Bibliometric Analysis Mapping the Evolution of Stem Cell Therapies for Diabetes Management
Orthopedics & Sports Medicine Sys. Review
Bibliometric Analysis Mapping the Evolution of Stem Cell Therapies for Diabetes Management Mapping the Growth and Trends of Stem Cell Therapy for Diabetes Research
A comprehensive review of 1,600 publications maps the evolution of stem cell and exosome therapies for Type 1 and Type 2 diabetes.
Scientists analyzed thousands of papers to track how stem cell treatments for diabetes have evolved over the last thirty years.
Frontiers Jul 24, 2026
Inflammation and immune dysregulation drive chronic kidney disease progression and associated tissue remodeling
Nephrology Sys. Review
Inflammation and immune dysregulation drive chronic kidney disease progression and associated tissue remodeling Inflammation and Immune Issues Drive Chronic Kidney Disease Progression
This mini review synthesizes the role of inflammation and immune dysregulation in the initiation and progression of chronic kidney disease. …
Persistent inflammation and immune system issues are central drivers of chronic kidney disease, leading to tissue damage and potential compl…
Frontiers Jul 24, 2026
Exercise ameliorates both type 1 and type 2 diabetes through multiple mechanisms
Diabetes & Endocrinology Sys. Review
Exercise ameliorates both type 1 and type 2 diabetes through multiple mechanisms Exercise Helps Manage Both Type 1 and Type 2 Diabetes
This narrative review summarizes how exercise improves glycemic control in both type 1 and type 2 diabetes through various mechanisms. Exerc…
Regular exercise serves as an affordable, low-risk way to help manage symptoms and complications for people living with both types of diabet…
Frontiers Jul 23, 2026
Liraglutide reduces stroke recurrence from 18.1% to 5.8% in patients with high insulin resistance
Neurology RCT
Liraglutide reduces stroke recurrence from 18.1% to 5.8% in patients with high insulin resistance Liraglutide reduces stroke risk for patients with insulin resistance
This post hoc analysis of a randomized controlled trial involved 510 patients with minor ischemic stroke or high-risk transient ischemic att…
A new analysis shows that the medication liraglutide significantly lowers stroke and vascular event risks for people with type 2 diabetes an…
Jul 22, 2026

Questions about Type 1 Diabetes

Does the FDA approved drug Tzield delay the onset of Stage 3 Type 1 diabetes?

Yes, the FDA-approved drug Tzield (teplizumab) delays the onset of Stage 3 type 1 diabetes in people with Stage 2 disease.

Full answer →
Can semaglutide help reduce the total daily insulin dose for adults with Type 1 diabetes?

Yes, semaglutide can reduce total daily insulin dose in adults with type 1 diabetes and overweight or obesity, based on clinical trial and real-world data.

Full answer →